Mr. Kirk has served as Executive Chairman of the Board since January 2020 and previously served as Chairman of the Board from February 2008 until January 2020 and as our CEO from April 2009 until January 2020. Mr. Kirk provides a wealth of strategic, operational, and management experience. Mr. Kirk currently serves as the Senior Managing Director and CEO of Third Security, LLC, an investment management firm founded by Mr. Kirk in March 1999. Additionally, Mr. Kirk founded and became Chairman of the Board of New River Pharmaceuticals Inc. (a biopharmaceutical company previously traded on Nasdaq prior to its acquisition by Shire plc in 2007) in 1996, and was President and CEO between October 2001 and April 2007.
Since May 2015, Mr. Kirk has served as a member of the board of directors of the Edward Via College of Osteopathic Medicine. Previously, Mr. Kirk served as a member of the board of directors of Scios, Inc. (previously traded on Nasdaq prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002, as a member of the board of directors of Halozyme Therapeutics, Inc. (Nasdaq: HALO), a clinical stage biotechnology company, from May 2007 to May 2018, as a member of the board of directors of ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biotechnology company, from January 2011 to October 2018, and as a member of the board of directors of Clinical Data, Inc. (previously traded on Nasdaq prior to its acquisition by Forest Laboratories, Inc. in April 2011) from September 2002 to April 2011, and was Chairman of the board of directors from December 2004 to April 2011.
Mr. Kirk served on the board of visitors of Radford University from July 2003 to June 2009, was Rector of the board of directors from September 2006 to September 2008 and served on the board of directors of the Radford University Foundation, Inc. from September 1998 to May 2011. He served on the board of visitors of the University of Virginia and Affiliated Schools from July 2009 to October 2012, on the Virginia Advisory Council on Revenue Estimates from July 2006 to October 2012 and on the Governor’s Economic Development and Jobs Creation Commission from April 2010 to October 2012. Mr. Kirk received a BA in Business from Radford University and a JD from the University of Virginia.
What is Randal J. Kirk's net worth?
The estimated net worth of Randal J. Kirk is at least $902,791.92 as of December 28th, 2023. Mr. Kirk owns 1,096,686 shares of Precigen stock worth more than $902,792 as of November 5th. This net worth evaluation does not reflect any other assets that Mr. Kirk may own. Additionally, Mr. Kirk receives a salary of $100,000.00 as Director at Precigen. Learn More about Randal J. Kirk's net worth.
How old is Randal J. Kirk?
What is Randal J. Kirk's salary?
As the Director of Precigen, Inc., Mr. Kirk earns $100,000.00 per year. There are 5 executives that earn more than Mr. Kirk. The highest earning executive at Precigen is Dr. Helen Sabzevari MPH, Ph.D., President, CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Randal J. Kirk's salary.
How do I contact Randal J. Kirk?
Has Randal J. Kirk been buying or selling shares of Precigen?
Randal J. Kirk has not been actively trading shares of Precigen during the last ninety days. Most recently, on Thursday, December 28th, Randal J. Kirk bought 96,686 shares of Precigen stock. The stock was acquired at an average cost of $1.41 per share, with a total value of $136,327.26. Following the completion of the transaction, the director now directly owns 1,096,686 shares of the company's stock, valued at $1,546,327.26. Learn More on Randal J. Kirk's trading history.
Who are Precigen's active insiders?
Are insiders buying or selling shares of Precigen?
In the last year, Precigen insiders bought shares 2 times. They purchased a total of 155,509 shares worth more than $186,326.81. The most recent insider tranaction occured on August, 9th when SVP Jeffrey Thomas Perez bought 58,823 shares worth more than $49,999.55. Insiders at Precigen own 44.9% of the company.
Learn More about insider trades at Precigen. Information on this page was last updated on 8/9/2024.
